Kairos Pharma, Ltd.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.4M | $-1.7M | $-1.4M | $-1.4M | $-1.4M | $-1.3M | $-980.0K | $-1.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $22.0K | $40.0K | $40.0K | $40.0K | $40.0K | $40.0K | $40.0K | $40.0K |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-1.0M | $-1.0M | $-1.1M | $-838.0K | $-805.0K | $-714.0K | $-1.8M | $-2.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-37.0K | $220.0K | $0 | $3.4M | $223.0K | $3.1M | $-142.0K | $5.2M |
| Net Change in Cash | $-1.0M | $-816.0K | $-1.1M | $2.5M | $-582.0K | $2.3M | $-1.9M | $3.2M |
| Free Cash Flow | — | — | — | — | — | — | — | — |